Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?

Executive Summary

Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.

Advertisement

Related Content

Allergan Performs Better Than Expected, But Still Conducting Strategic Review
Biopharma Quarterly Dealmaking Statistics, Q3 2016
Stockwatch: Has Sentiment Left the Biopharma Sector?
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
Vitae's Vagueness On Psoriasis Program Spooks Investors
Vitae Focused On Psoriasis After BI Terminates Collaboration
BioNotebook: Four financings, layoffs at Regado and four IPO updates
Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders
Autoimmune RORγt Program May Portend Change Of Direction For Vitae

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel